(Q46896444)

26 December 2017

title

Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. (English)

1 reference

26 December 2017

0 references

1 reference

4

1 reference

26 December 2017

Stephen F Previs

series ordinal

3

object named as

Stephen F Previs

1 reference

26 December 2017

author name string

Rodney A Velliquette

series ordinal

1

1 reference

26 December 2017

Rachel Kossover

series ordinal

2

1 reference

26 December 2017

publication date

17 January 2006

1 reference

26 December 2017

Naunyn-Schmiedeberg's Archives of Pharmacology

published in

1 reference

26 December 2017

volume

372

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

page(s)

300-312

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s00210-005-0024-3

exact match

0 references

cites work

Influence of diet on the modeling of adipose tissue triglycerides during growth

1 reference

https://api.crossref.org/works/10.1007%2FS00210-005-0024-3

The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-005-0024-3

Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-005-0024-3

The role of Kupffer cell alpha(2)-adrenoceptors in norepinephrine-induced TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-005-0024-3

The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs

21 January 2018

1 reference

12 December 2020

Imidazoline compounds stimulate insulin release by inhibition of K(ATP) channels and interaction with the exocytotic machinery

1 reference

12 December 2020

Moxonidine improves insulin sensitivity in insulin-resistant hypertensives

1 reference

12 December 2020

Role of vascular alpha 2-adrenoceptors as targets for circulating catecholamines in the maintenance of blood pressure in anaesthetised spontaneously hypertensive rats

1 reference

12 December 2020

Metabolism and disposition of moxonidine in Fischer 344 rats

1 reference

12 December 2020

Nonadrenergic imidazoline binding sites and amine oxidase activities in fat cells

1 reference

12 December 2020

Effect of I1-imidazoline receptor activation on responses of hypoglossal and phrenic nerve to chemical stimulation.

1 reference

12 December 2020

Aspects of tolerability of centrally acting antihypertensive drugs

1 reference

12 December 2020

The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.

1 reference

12 December 2020

Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats

1 reference

12 December 2020

Gas chromatography-mass spectrometry assay of the (18)o enrichment of water as trimethyl phosphate

1 reference

12 December 2020

Contrasting metabolic effects of antihypertensive agents.

1 reference

12 December 2020

Two generations of insulinotropic imidazoline compounds

1 reference

12 December 2020

Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine.

1 reference

12 December 2020

Mechanism of differential effects of antihypertensive agents on serum lipids

1 reference

12 December 2020

Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome.

1 reference

12 December 2020

Moxonidine: a review of safety and tolerability after seven years of clinical experience

1 reference

12 December 2020

Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure

1 reference

12 December 2020

Effect of moxonidine on lipid subfractions in patients with hypertension

1 reference

12 December 2020

Imidazoline receptors in rat liver cells: a novel receptor or a subtype of alpha 2-adrenoceptors?

1 reference

12 December 2020

The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene: lanosterol cyclase activity

1 reference

12 December 2020

Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.

1 reference

12 December 2020

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

12 December 2020

Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells

1 reference

12 December 2020

Moxonidine: pharmacology, clinical pharmacology and clinical profile

1 reference

12 December 2020

Non-adrenergic sites for imidazolines are not directly involved in the alpha 2-adrenergic antilipolytic effect of UK 14304 in rat adipocytes.

1 reference

12 December 2020

Imidazoline antihypertensive drugs: a critical review on their mechanism of action

1 reference

12 December 2020

Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).

1 reference

12 December 2020

Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes

1 reference

12 December 2020

Inhibition of Hepatic Cholesterol and Triglyceride Synthesis by Guanabenz Acetate

1 reference

12 December 2020

High level of alpha2-adrenoceptor in rat foetal liver and placenta is due to alpha2B-subtype expression in haematopoietic cells of the erythrocyte lineage

1 reference

12 December 2020

I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly

1 reference

12 December 2020

Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)

1 reference

12 December 2020

Relationship of guanabenz concentrations in brain and plasma to antihypertensive effect in the spontaneously hypertensive rat.

1 reference

12 December 2020

Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes.

1 reference

12 December 2020

Effect of moxonidine on parameters of lipid metabolism in patients with metabolic syndrome

1 reference

12 December 2020

Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent

1 reference

12 December 2020

Relationship between I2 imidazoline binding sites and monoamine oxidase B in liver.

1 reference

12 December 2020

Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat.

1 reference

12 December 2020

alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice

1 reference

12 December 2020

Optimization of radioligand binding assays for I1-imidazoline sites

1 reference

12 December 2020

Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists

1 reference

12 December 2020

Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.

1 reference

12 December 2020

Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice

1 reference

12 December 2020

Assembly of very low density lipoproteins in mouse liver: evidence of heterogeneity of particle density in the Golgi apparatus

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

Imidazoline receptor antisera-selected cDNA clone and mRNA distribution.

1 reference

12 December 2020

Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes

1 reference

12 December 2020

Safety and tolerability of moxonidine in the treatment of hypertension.

1 reference

12 December 2020

Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan

1 reference

12 December 2020

10.1007/S00210-005-0024-3

Identifiers

DOI

1 reference

26 December 2017

release_q3tsfktrvnhhrp7vudkdjn5x6y

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q3tsfktrvnhhrp7vudkdjn5x6y

24 November 2022

mapped directly with Wikidata item

PubMed ID

16416266

1 reference

26 December 2017